Gan & Lee Pharmaceuticals: all 56 studies

Page 1 of 1. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• A Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of GLR1075 Injection in Healthy Trial Participants and Cirrhotic Trial Participants With Ascites and HypoalbuminemiaNot yet recruitingNCT07851688Phase 1
• A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study ParticipantsRecruitingNCT07784699Phase 1
• Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult ParticipantsNot yet recruitingNCT07670897Phase 1
• Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 DiabetesRecruitingNCT07527078Phase 3
• Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) TherapyNot yet recruitingNCT07501832Phase 3
• Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) TherapyNot yet recruitingNCT07493057Phase 3
• A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate CancerNot yet recruitingNCT07468396Phase 1
• Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 DiabetesNot yet recruitingNCT07387003Phase 2
• Bioequivalence Study of GZR18 Injection Before and After CMC ChangeRecruitingNCT07355738Phase 1
• A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male SubjectsNot yet recruitingNCT07334496Phase 1
• Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossRecruitingNCT07292441Phase 3
• Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady StateRecruitingNCT07242664Phase 1
• A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinRecruitingNCT07165223Phase 3
• Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight SubjectsRecruitingNCT07150975Phase 3
• Comparison Study of Insulin GZR4 With Insulin DegludecRecruitingNCT07146347Phase 1
• Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver FunctionRecruitingNCT07144098Phase 1
• Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal FunctionRecruitingNCT07141030Phase 1
• Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionRecruitingNCT07128888Phase 1
• A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight SubjectsNot yet recruitingNCT06974487Phase 1
• A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic AcidRecruitingNCT06780410Phase 3
• A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese SubjectsNot yet recruitingNCT06670209Phase 1
• A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection ODRecruitingNCT06558708Phase 2
• A Study of GZR4 Injection at Different Injection SitesRecruitingNCT06548906Phase 1
• Gan & Lee Insulin Glargine Target Type (2) Evaluating ResearchCompletedNCT03371108Phase 3Results posted
• Gan & Lee Insulin Glargine Target Type (1) Evaluating ResearchCompletedNCT03371082Phase 3Results posted
• Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic ImpairmentActive, not recruitingNCT07193147Phase 1
• The Study of [14C] GZR18CompletedNCT07119450Phase 1
• A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes MellitusActive, not recruitingNCT07055386Phase 2
• A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusActive, not recruitingNCT06778967Phase 3
• A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExerciseActive, not recruitingNCT06777238Phase 3
• A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial InsulinActive, not recruitingNCT06767761Phase 3
• A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinActive, not recruitingNCT06767748Phase 3
• A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)Active, not recruitingNCT06767735Phase 3
• Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight ParticipantsCompletedNCT06737042Phase 2
• A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsActive, not recruitingNCT06728124Phase 3
• A Clinical Study of GZR33 and GZR101 in Healthy SubjectsCompletedNCT06556641Phase 1
• A Study of GZR18 Tablet in Chinese Healthy SubjectsActive, not recruitingNCT06554054Phase 1
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 DiabetesCompletedNCT06553248Phase 1
• A Phase I Study of GZR18 Injection in Healthy SubjectsCompletedNCT06548997Phase 1
• A Phase I Study of GZR18 Injection in Obese/Overweight SubjectsCompletedNCT06548945Phase 1
• A Study to Evaluate the Safety, Tolerance, PK and PD Parameters of GZR33 and GZR101 in Healthy Male Adult SubjectsCompletedNCT06548932Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4CompletedNCT06548815Phase 1
• Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal ImpairmentCompletedNCT06547502Phase 1
• A Study of GZR18 Injection in Obese/Overweight PatientsCompletedNCT06256562Phase 2
• A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes MellitusActive, not recruitingNCT06256549Phase 2
• A Study of GZR18 Injection in Chinese Obese/Overweight PatientsCompletedNCT06256536Phase 1/2
• A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)CompletedNCT06256523Phase 1/2
• A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes MellitusCompletedNCT06202079Phase 2
• A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DMCompletedNCT06199505Phase 2
• Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy SubjectsCompletedNCT05328726Phase 1
• Evaluation of GLR2007 for Advanced Solid TumorsCompletedNCT04444427Phase 1/2
• Gan & Lee Evaluation of New Biosimilar for Type 1 LisproWithdrawnNCT04254380Phase 3
• PK/PD Study of Gan & Lee Insulin Aspart Injection vs. US & EU NovoLog®/NovoRapid® in Healthy MalesCompletedNCT04237129Phase 1
• PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus PatientsCompletedNCT04236895Phase 1
• PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy MalesCompletedNCT04235439Phase 1
• PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 DiabetesCompletedNCT02506647Phase 1

← Gan & Lee Pharmaceuticals overview and focus areas